

**REMARKS**

Claims 1-20 are pending in this application. By this amendment, claims 2-6, 15-17 and 20 have been canceled and claims 1, 13 and 14 have been amended without prejudice or disclaimer to renewal, leaving claims 1, 7-14 and 18-19 pending. Applicants have also updated the priority claim.

Support for the claim amendments is found, *inter alia*, throughout the specification, for example, support for the amendment to claim 1 can be found at page 6, lines 4-7, and at pages 45-47, Example 2. The amendment of claim 13 is to correct a clerical error. The amendment to claim 14 is to define specific “benzoporphyrin derivatives” where possible. The particular BPDs recited in the claim are known by the identifiers used and are disclosed in the specification at least on pages 22-24 of the specification and the references cited therein.

The amendments are made solely to promote prosecution without prejudice or disclaimer of any previously claimed subject matter. With respect to all amendments and cancelled claims, Applicants have not dedicated or abandoned any unclaimed subject matter and moreover have not acquiesced to any rejections and/or objections made by the Patent Office. Applicants expressly reserve the right to pursue prosecution of any presently excluded subject matter or claim embodiments in one or more future continuation and/or divisional application(s).

Applicants respectfully request examination of the application on the merits.

**CONCLUSION**

In the event that there are any questions concerning this amendment or the application in general, the Examiner is respectfully urged to telephone the undersigned representative so that prosecution may be expedited.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 273012011601. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April 1, 2004

Respectfully submitted,

By Karen R Zachow  
Karen Zachow

Registration No.: 46,332  
MORRISON & FOERSTER LLP  
3811 Valley Centre Drive, Suite 500  
San Diego, California 92130  
(858) 720-5191